Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
138.42(c) 138.12(c) 138.76(c) 139.79(c) 138.85(c) Last
4 771 127 4 859 048 5 456 839 6 951 797 5 382 091 Volume
-0.14% -0.22% +0.46% +0.74% -0.67% Change
More quotes
Financials (USD)
Sales 2019 81 174 M
EBIT 2019 25 487 M
Net income 2019 19 737 M
Debt 2019 9 323 M
Yield 2019 2,70%
Sales 2020 84 655 M
EBIT 2020 27 898 M
Net income 2020 21 550 M
Finance 2020 5 646 M
Yield 2020 2,88%
P/E ratio 2019 19,53
P/E ratio 2020 17,75
EV / Sales2019 4,66x
EV / Sales2020 4,29x
Capitalization 369 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (49.9%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
05/30 | 12:00pmPresentation
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
12:56pJOHNSON & JOHNSON : Teva settles with Oklahoma for $85 million in opioid case
AQ
05/25JOHNSON & JOHNSON : Taiwanese startups receive boost from French, Swiss health i..
AQ
05/24JOHNSON & JOHNSON : to Participate in Bernstein's 35th Annual Strategic Decision..
AQ
05/24NUEVOLUTION PUBL : Amgen bids $167M to buy drug discovery shop Nuevolution
AQ
05/24JOHNSON & JOHNSON : Ex-dividend day for
FA
05/23JOHNSON & JOHNSON : Drug-Resistant TB Having Heavy Toll On Economies
AQ
05/23JOHNSON & JOHNSON : Taiwanese Startups Receive 4.5 Million Euros from Swiss & Fr..
AQ
05/23JOHNSON & JOHNSON : Janssen Pharmaceutical - U.S. FDA Grants Priority Review of ..
AQ
05/22JOHNSON & JOHNSON : J&J Unit Gets FDA Priority Review of Invokana in Chronic Kid..
DJ
05/22JOHNSON & JOHNSON : Janssen Pharmaceutical - New Data Highlights the Value of SP..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
12:36pTEVA PHARMACEUTICAL INDUSTRIES : Settles Oklahoma Opioid Case for $85 Million --..
DJ
12:25pTEVA PHARMACEUTICAL INDUSTRIES : Settles Oklahoma Opioid Case for $85 Million
DJ
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 148 $
Spread / Average Target 6,5%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.32%368 655
PFIZER-3.96%233 239
ROCHE HOLDING LTD.11.42%233 096
NOVARTIS17.44%219 832
MERCK AND COMPANY6.23%208 984
ABBVIE-13.16%118 355